Krishna Ayurveda · India go-to-market · October 2026
Canso Shield: the rules first, then the plan
Indian law decides what we can say about this juice. Start with the rules below, tick off what is already in place, and the page shows which plan you can start now and what is still blocking the others.
This is a planning guide, not legal advice. Laws are summarised from general knowledge and must be confirmed by a regulatory lawyer before any launch.
1The legal ground rules
In India, no product may be advertised as treating or preventing cancer. A disclaimer like "we don't claim a cure" does not help. Regulators judge the overall impression, including the product name.
Never say or show in public
Cancer ShieldCanso Shieldcancertumourdissolves growthsreduces tumour sizeworks like immunotherapychemo supportcure"doctors had given up"before/after scans
This covers ads, videos, reels, website pages, WhatsApp broadcasts, influencer posts and free-sample offers.
Allowed, with a reviewed claims sheet
supports natural immunitytraditional rasayana formulaherbs and amountslab-tested every batchreviewed by our vaidyataste and ease of use
Also allowed: one-to-one advice from a qualified vaidya, scientific material for registered doctors, and registered research.
| Law or rule | In plain words | What it means for us |
|---|---|---|
| Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 | Cancer is on the list of diseases that no remedy may be advertised for. Fines and jail are possible. | No public link between the juice and cancer, anywhere. |
| Drugs & Cosmetics Act (AYUSH licensing) | Ayurvedic medicines need the right licence and GMP (Schedule T). | Confirm the licence category before any health positioning. |
| FSSAI advertising and nutraceutical rules | If sold as a food or juice, disease claims are banned. | Only general wellness claims. |
| Consumer Protection Act 2019 + CCPA misleading-ad guidelines | Misleading claims and endorsements are penalised. Endorsers must have used the product. | Brand and influencers can both be fined. |
| ASCI code | Advertising standards body; complaints and rulings are public. | Check every campaign against the claims sheet. |
| Supreme Court, Patanjali case (2024) | Ordered states to enforce health-ad laws strictly. | Enforcement risk is higher than before. |
| DPDP Act 2023 | Personal and health data needs consent and safe storage. | Applies to all patient feedback. |
| Meta and Google ad policies | Restrict unproven medical treatments and health-condition targeting. | Ads with "cancer" get rejected; accounts can be banned. |
Before anything else this week: hold the owner's video, hold the public "free bottles for cancer patients" listing, and pick a new name with no link to any disease.
2Experts to consult and approvals to get first
Consult in this order. The lawyer and the regulatory consultant come first because their answers decide which approvals you need and which plans are possible.
Experts, in the order to consult them
| Expert and level | Why we need them | When | Plans |
|---|---|---|---|
| Healthcare regulatory lawyer (experience with Drugs & Cosmetics Act, DMR Act, CCPA and ASCI cases) | Confirms what can be said, reviews the name, the claims sheet and the vaidya programme model. | Week 1 | All |
| AYUSH regulatory consultant (licensing with the State Licensing Authority) | Decides AYUSH medicine vs FSSAI food route and handles licences, labelling and GMP. | Week 1–2 | All |
| Senior Ayurvedic physician: BAMS + MD (Ayurveda), ideally Kayachikitsa or Rasayana, with experience supporting cancer patients | Writes the protocol, dose, who should not take it, and reviews all product content. | Week 2 | B, C, A |
| Medical oncologist adviser: MD + DM (Medical Oncology) | Checks safety alongside chemo and radiation, sets exclusion rules, and gives the programme medical credibility. | Month 1 | C, A |
| Clinical pharmacologist or pharmacognosy expert (PhD / MD Pharmacology) | Reviews herb–drug interactions, herb identity and standardisation of the formula. | Month 1 | C, A |
| Quality assurance head + NABL-accredited lab | Batch testing for heavy metals, microbes, pesticides and aflatoxin; shelf-life data. | Week 2 onwards | All |
| Data protection adviser | Consent wording and secure storage for patient data under the DPDP Act. | Month 1 | C, A |
| Clinical research organisation (CRO) + biostatistician | Designs the study, sample size and analysis; manages ethics and CTRI paperwork. | Month 2–4 | A |
| Institutional Ethics Committee (registered with the authorities) | Approves the study protocol and consent before any patient is enrolled. | Month 3–5 | A |
Approvals and credentials, in order
| Approval or credential | Issued by | Status needed | Plans |
|---|---|---|---|
| Ayurvedic manufacturing licence covering this product, or FSSAI licence if sold as food | State AYUSH Licensing Authority / FSSAI | Must have | All |
| Product approval as a proprietary Ayurvedic medicine (with safety and effectiveness data), or FSSAI nutraceutical category compliance | State AYUSH Licensing Authority / FSSAI | Must have | All |
| GMP certificate (Schedule T for Ayurvedic manufacturing) | State AYUSH Licensing Authority | Must have | All |
| Compliant label: ingredients, dose, licence number, batch, expiry, cautions | As per AYUSH or FSSAI labelling rules | Must have | All |
| NABL-accredited batch test reports | NABL-accredited laboratory | Must have | All |
| Trademark registration for the new name | Trade Marks Registry, India | Must have before launch | B |
| Signed-off claims sheet | Regulatory lawyer (checked against ASCI code) | Must have | B |
| Registration with the AYUSH pharmacovigilance programme (side-effect reporting) | Ministry of AYUSH programme centres | Must have | C, A |
| Patient consent form and data policy | Drafted with lawyer and data adviser | Must have | C, A |
| Ethics committee approval | Institutional Ethics Committee | Must have before study | A |
| Clinical trial registration | CTRI (Clinical Trials Registry of India) | Must have before study | A |
| ISO 22000 / HACCP, AYUSH quality mark, WHO-GMP | Certification bodies / QCI | Good to have; builds trust | All |
| Research partnership agreement | CCRAS, AIIA or an Ayurveda college hospital | Good to have; needed for credibility | A |
Exact forms, rules and the current status of AYUSH advertising rules change often. The lawyer and regulatory consultant should confirm this list in week 1.
3Check your conditions
Tick what is already done. Each plan turns green when its conditions are met. The tags show which plan needs each item.
4Act on each plan
Plan B earns revenue, Plan C serves patients safely and collects data, Plan A turns that data into credibility. They can run side by side.
Plan B: sell it as a general immunity juice
Same formula, new name, wellness claims only. Fastest legal route to revenue. It cannot target cancer patients.
Start only when
- New name chosen, trademark search clear
- Licence category confirmed
- Claims sheet signed off
- Batch lab reports in hand
Who it reaches
- Immunity and wellness buyers, metro and tier-2/3
- Existing Krishna customers
- Rename the productWeek 1–2Drop "Cancer" and "Canso". Choose a herb- or strength-based name.
- Approve the claims sheetWeek 2Allowed and banned phrases, signed by a regulatory reviewer. Every ad is checked against it.
- Rebuild the product pageWeek 3Herbs and amounts as text, dosage, who should avoid it, lab reports, vaidya reviewer, FAQs.
- Check overlap with the immunity rangeWeek 3Position as the premium rasayana tier or bundle it.
- Launch on website and marketplacesWeek 4–8Website, Amazon, Flipkart, quick commerce, WhatsApp to existing customers.
- Start immunity adsWeek 6+Meta and Google on general immunity. No health-condition targeting. Scale on cost per order.
- Run the reviews engineWeek 4+Insert card QR, WhatsApp asks on day 7 and 30, disclosed small reward, publish all reviews.
Stop and fix if: any staff member, influencer or reviewer links the product to cancer in public.
Plan C: reach patients only through a vaidya
Replaces the public free-bottle offer. Patients get the juice after a consultation, with their oncologist informed, and every case gives structured feedback.
Start only when
- Clinical protocol written
- Consent form ready (Hindi and English)
- Side-effect logging process in place
- Batch lab reports in hand
- Oncologist adviser on board
- Lawyer has reviewed the model
Who it reaches
- Patients and caregivers who book a consultation
- Referrals from Ayurveda hospitals and integrative clinics
- Write the clinical protocolMonth 1Who qualifies, who must not take it, dose, when to stop.
- Prepare the consent formMonth 1Supportive care only; continue your oncologist's treatment; report side effects; data use.
- Intake through a vaidya consultationMonth 2Record diagnosis, stage, current treatment and baseline scores before dispatch.
- Follow up on a fixed scheduleMonth 2+Week 2, 4, 8 and 12, same questions each time.
- Log and report side effectsMonth 2+Within 24 hours; report to the AYUSH pharmacovigilance programme.
- Give the free bottles through this programmeMonth 2+The 10–15k bottles go to enrolled patients, not a public listing.
- Add referral partnersMonth 3+Ayurveda hospitals, integrative clinics, palliative-care groups. Education material, not ads.
- Offer patient support extrasMonth 3+Diet plans during chemo, caregiver guidance, a helpline.
- Hand the data to Plan AMonth 6+After 300–500 complete records, share anonymised data with the research partner.
Stop and review if: a serious side effect is reported, or the programme starts being promoted publicly as a cancer service.
Plan A: build evidence an institution will stand behind
The only route that could later let the brand speak to doctors about cancer support.
Start only when
- Product dossier complete
- Licence category confirmed
- Research partner signed
- Ethics approval and CTRI registration
- Budget approved
Who it reaches
- Oncologists and Ayurvedic physicians
- CCRAS, AIIA, Ayurveda college hospitals
- Build the product dossierMonth 1–2Formula with Latin herb names, classical references, process, shelf life, NABL tests.
- Fix the licence categoryMonth 1–3AYUSH proprietary medicine is needed for any therapeutic positioning.
- Choose a research partnerMonth 2–4An Ayurveda college hospital with an oncology unit, CCRAS, AIIA or an integrative clinic.
- Get ethics approval and register on CTRIMonth 3–5100–200 patients on standard treatment; quality of life, fatigue, appetite, blood counts, chemo completion, side effects.
- Run the studyMonth 6–15The hospital collects clinical data; Krishna's vaidyas help with follow-up.
- Publish the resultsMonth 15–20In an indexed journal, positive or negative.
- Present to doctorsMonth 18+Detailing, CME talks, conference posters. Patient ads stay off-limits.
- Fund a randomised trial if results are strongLaterThe evidence level needed for wider claims.
Accept the outcome: results may be neutral. That is still worth knowing before scaling.
5Red flags: stop and call the lawyer
A review mentions cancer or a tumourDo not publish or share it. Thank the customer privately and log it as patient feedback.
An influencer wants to tell a "cancer story"Decline. The brand is liable for their words under CCPA rules.
An ad platform rejects an ad for health claimsRewrite against the claims sheet. Do not try to bypass the review.
A patient stops chemotherapy to use the juiceThe vaidya contacts them and urges them to continue with their oncologist.
A serious side effect is reportedLog it within 24 hours, report to AYUSH pharmacovigilance, review the batch.
Media or a regulator contacts the companyRoute to the lawyer before anyone replies.